Download Wnt Reporter Assay - Enzo Life Sciences

Wnt Reporter Assay
New Leading Light™ Wnt Reporter Assay with the Highest Sensitivity
Leading Light™ Wnt Reporter Assay (ENZ-61001)
Screen-Well® Wnt Pathway Compound Library (BML-2838)
Recombinant Wnt-3a (mouse) (ENZ-60001)
Recombinant DKK-1 (mouse) (ENZ-60002)
You asked. We delivered. Enzo’s new Leading Light™ Wnt Reporter Assay was developed to meet the market need for a high sensitivity system
that accelerates screening analysis of Wnt pathway modulators. This product is a luciferase-based assay for the analysis of canonical Wnt signaling.




Highest Sensitivity in response to Wnt effectors without the use of lithium chloride
Highly active Wnt-3a protein included to ensure robust signal
96- or 384-well format allows high throughput analysis of Wnt pathway effectors
Validated kit provides cells, media, reagents and controls ensuring reproducible results
Enzo Life Sciences: A Leader in Providing Enhanced
Sensitivity Detection Platforms to Scientists
The addition of our new Leading Light™ Wnt Reporter Assay
continues this mission of providing high-value tools to the research
community to enable discovery for a variety of clinically relevant
disease states, including cancer, osteoporosis, cardiovascular
disease, diabetes, and neurodegeneration. Discover more with this
pioneering, sensitive assay for screening Wnt modulators, as well as
a supporting portfolio of ELISA kits and reagents to help you monitor
Wnt signaling from cell surface to nucleus.
Greater Sensitivity with a Superior Signal-to-noise Ratio
The Leading Light™ Reporter Assay yields a greater than 12-fold
increase in signal over background, surpassing the signal intensity of
other commercially available reporter assays. A robust signal-to-noise
ratio allows for enhanced detection of Wnt pathway modulators.
Figure 1: Signal intensity of
Leading Light™ versus
competitor.
When treated with 100 ng/mL
of Wnt-3a (ENZ-60001), the
Leading Light Reporter Assay
yielded greater than 12-fold
increase in signal. The foldinduction for Company 1 was
determined using published
product information for their
Wnt-3a protein and reporter
assay.
Figure 2: Dose response of Leading Light™ Wnt Reporter Cells to Wnt3a and Dkk-1 proteins. (A) Leading Light™ Wnt Reporter Cells were
treated with indicated doses of Wnt-3a protein (ENZ-60001) for six hours.
The chemiluminescence in the Wnt-3a-treated cells increased in a dosedependent manner. (B) Cells were treated with the indicated doses of Dkk-1
in the presence of 200 ng/mL Wnt-3a. Dkk-1 inhibits Wnt-3a-elevated
luciferase levels in a dose dependent manner.
Enzo Highly Active Proteins Outperform the Competition
The Leading Light™ Wnt Reporter Assay includes cells, media, and
detection reagents required for testing. Additionally, active Wnt-3a
and Dkk-1 are provided as controls. In a head-to-head comparison,
Enzo recombinant Wnt-3a protein had greater activity versus an
identical recombinant protein from a competitor.
*
*
Dynamic range of signal with No Artificial Signal Enhancement
The Leading Light™ Wnt Reporter Assay includes an engineered 3T3
mouse fibroblast cell line with a luciferase reporter gene under the
control of a Wnt responsive promoter. This optimized system requires
no lithium chloride to boost signal, ensuring confidence in Wnt
pathway screening results.
Figure 3: Comparison of Wnt-3a protein activity. Leading
Light™ Wnt Reporter Cells were treated with indicated doses
of Wn-t3a protein (ENZ-60001 or competitor product). The
chemiluminescence in the Wnt-3a-treated cells increased in a
dose-dependent manner.*, denotes significant different as
measured by a student t-test.
The Next Big Thing for Wnt Research is Here!
1
For more detailed product information, please visit: www.enzolifesciences.com
Wnt Reporter Assay
Reproducible Results from a Validated System
The Leading Light™ Wnt Reporter Assay was validated by detecting Wnt activation of an endogenous Wnt target gene, TGF-β2. Pathway activation
or inhibition was modulated using a small molecule control, IIIC3, which inhibits Dkk-1 binding, and Wnt ligands (Wnt-3a and Dkk-1).
A
B
Figure 4. Validated system for screening small molecules. Leading Light Reporter Cells were seeded and incubated at 37°C overnight. After 24h, cells were treated
with Wnt-3a, Wnt-3a + DKK-1, and Wnt-3a + DKK-1 + (3.3 or 10 µM) IIIC3 (DKK-1 inhibitor) for 6 hours at 37°C. Untreated cells were used as a background control. After
6h treatment, the chemiluminescence in each conditioned sample was measured using the detection reagents (A). In an identical experiment following treatment, cells in
each well were harvested and total RNA was isolated (B). Real-time RT-PCR was performed to detect mRNA level of TGF-β2 (Wnt target gene) in each sample. TGF-β2
mRNA levels in each sample were normalized against β-actin levels of mRNA.
Let Enzo Provide Your Wnt Research Solution
Enzo has provided reliable, consistent, and innovative
products to researchers for almost 40 years. We are
dedicated to expanding the field of Wnt research by offering
novel products, thoughtful application data and peer-reviewed
publications. The Leading Light™ Wnt Reporter Assay along
with the Screen-Well® Wnt Pathway Library and numerous
ELISAs, antibodies and proteins combine to provide a total
solution for Wnt pathway-related researchers.
With our broad array of research tools, Enzo provides high-purity,
high-sensitivity reagents applicable to the following Wnt Pathway
areas of interest:
 Assessing functions and activities of various Wnt-related
ligands
 Compound screening of small molecules and antibodies for
identification of Wnt inhibitors or agonist
 Drug screen of small molecules that modulate the Wnt
signaling pathway
 Analysis of RNAi or gene expression phenotypes
Application Note:
Cell-Based Screening of Focused Bioactive Compound Libraries: Assessing Small Molecule
Modulators of the Canonical Wnt Signaling and Autophagy-Lysosome Pathways
Article:
Li, X et al. Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in
regulation of glucose metabolism. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11402-7.
Enzo is continually adding new products to our Wnt portfolio. Check back with us
soon to learn about our next generation binding assays and compounds to support
Wnt pathway analysis!
The Next Big Thing for Wnt Research is Here!
For more detailed product information, please visit: www.enzolifesciences.com
2